Scancell narrows loss as it progresses immunotherapy pipeline
By Josh White
Date: Thursday 11 Sep 2025
(Sharecast News) - Scancell reported progress across its immunotherapy pipeline on Thursday, as it narrowed annual losses and prepared for late-stage development of its lead melanoma treatment.
The AIM-traded biotech said its DNA ImmunoBody candidate iSCIB1+ delivered positive phase two results in the SCOPE trial, showing an 11-month progression-free survival rate of 78% in the target HLA population, compared with historic 12-month rates of 46% from standard doublet checkpoint therapy.
Combined data across cohorts showed 22-month progression-free survival of 69%, with favourable safety and improved overall and disease control response rates.
The therapy had been selected for further development, expanding its potential patient reach to 80% of late-stage melanoma cases, with randomised registration studies expected to begin in 2026.
Early data from the Moditope Modi-1 candidate in the Phase 2 ModiFY trial also showed encouraging signs, with a 43% response rate in head and neck cancer when combined with a single checkpoint inhibitor.
Recruitment continues in renal cell carcinoma using Modi-1 with doublet checkpoint therapy, with further results expected in the fourth quarter.
The company said it had developed robust, scalable formulations for both iSCIB1+ and Modi-1 to support their advancement.
Scancell said it had also advanced its GlyMab antibody platform, incorporating it into a new wholly owned subsidiary, GlyMab Therapeutics.
It secured a second commercial licence with Genmab for antibody SC2811 worth $6m upfront and up to $630m in milestones plus royalties, while development of the first partnered antibody SC129 remains on track.
The company reported an operating loss of £15m for the year to 30 April, narrowed from £18.3m, and ended the period with £16.9m in cash following a £11.3m fundraise in late 2024.
It said it had sufficient funding into the second half of 2026 and is assessing partnering and out-licensing opportunities.
Chief executive Phillip L'Huillier said Scancell was "making strong clinical and organisational progress" and that iSCIB1+ had shown "significant potential to address the unmet needs of advanced melanoma patients, with a clinically meaningful improvement on progression free survival over standard of care".
He added the company was accelerating preparations for registration studies and "determined to realise the potential of our active immunotherapies for patients on our mission towards a cancer-free future".
At 1400 BST, shares in Scancell Holdings were down 3.98% at 8.2p.
Reporting by Josh White for Sharecast.com.
Email this article to a friend
or share it with one of these popular networks:
You are here: news
10 Lower Thames St,
London EC3R 6EN